Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Clinical roles of calcium channel blockers in ischemic heart diseases

Abstract

Calcium (Ca) channel blockers (CCBs) inhibit Ca2+ channels in the myocardium or vascular smooth muscle cells, inhibit myocardium contraction, inhibit the impulse conduction system (anti-arrhythmias) and cause vasodilation. New classifications based on subtypes of Ca channels and α1 subunits have been proposed. Moreover, CCBs have pleiotropic effects on coronary spastic angina (CSA), including variant angina, myocardial infarction (MI) and stent thrombosis (ST). Although the roles of CCBs in clinical situations remain unknown, further studies in this field are expected to broaden our understanding. In this article, we explain the clinical roles of CCBs in ischemic heart diseases, such as CSA, MI and ST, based on previous knowledge and as demonstrated in representative clinical trials.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1

References

  1. 1

    Fleckenstein A, Nakayama K, Fleckenstein-Grün G, Byon Y . Interactions of H ions, Ca-antagonistic drugs and cardiac glycosides with excitation-contraction coupling of vascular smooth muscle Ionic actions on vascular smooth muscle. Springer 1976, 117–123.

  2. 2

    Vater W, Kroneberg G, Hoffmeister F, Saller H, Meng K, Oberdorf A, Puls W, Schlossmann K, Stoepel K . Pharmacology of 4-(2'-nitrophenyl)-2, 6-dimethyl-1, 4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester (Nifedipine, BAY a 1040). Arzneimittel-Forschung 1972; 22: 1–14.

    CAS  PubMed  Google Scholar 

  3. 3

    Fleckenstein A, Tritthart H, Döring H-J, Byron KY . BAY a 1040 — ein hochaktiver Ca++-antagonistischer Inhibitor der elektro-mechanischen Koppelungsprozesse im Warmblüter-Myocard. Arzneimittelforsch 1972; 22: 22–23.

    CAS  PubMed  Google Scholar 

  4. 4

    Hashimoto K, Taira N, Sato S, Chiba S, Hashimoto K, Tamura K, Endoh M, Iijima T . Pharmacological action on nitrophenyi-dimethyl-dihydropyridine-deri-vatlve. Heart 1971; 3: 1294–1304.

    Google Scholar 

  5. 5

    Murakami M, Murakami E, Takekoshi N, Tsuchiya M, Kin T, Onoe T, Takeuchi N, Funatsu T, Hara S, Ishise S . Antihypertensive effect of 4 (-2'-nitrophenyl)-2, 6-dimethyl-1, 4-dihydropyridine-3, 5-dicarbonic acid dimethylester (nifedipine, bay-a 1040), a new coronary dilator. Jpn Heart J 1972; 13: 128–135.

    Article  CAS  PubMed  Google Scholar 

  6. 6

    Aoki K, Yoshida T, Kato S, Tazumi K, Sato I, Takikawa K, Hotta K . Hypotensive action and increased plasma renin activity by Ca2+ antagonist (nifedipine) in hypertensive patients. Jpn Heart J 1976; 17: 479–484.

    Article  CAS  PubMed  Google Scholar 

  7. 7

    Sato M, Nagao T, Yamaguchi I, Nakajima H, Kiyomoto A . Pharmacological studies on a new l, 5-benzothiazepine derivative (CRD-401). Arzneimittelforschung 1971; 21: 1338.

    CAS  PubMed  Google Scholar 

  8. 8

    Yasue H, Takizawa A, Nagao M, Nishida S, Horie M, Kubota J, Omote S, Takaoka K, Okumura K . Long-term prognosis for patients with variant angina and influential factors. Circulation 1988; 78: 1–9.

    Article  CAS  PubMed  Google Scholar 

  9. 9

    Hayashi K, Wakino S, Sugano N, Ozawa Y, Homma K, Saruta T . Ca2+ channel subtypes and pharmacology in the kidney. Circ Res 2007; 100: 342–353.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. 10

    Cosnier D, Duchenne-Marullaz P, Rispat G, Streichenberger G . Cardiovascular pharmacology of bepridil (1 [3 isobutoxy 2 (benzylphenyl) amino] propyl pyrrolidine hydrochloride) a new potential anti-anginal compound. Arch Int Pharmacodyn Ther 1977; 225: 133–151.

    CAS  PubMed  Google Scholar 

  11. 11

    Yamamoto E, Nakamura T, Kataoka K, Tokutomi Y, Dong Y-F, Fukuda M, Nako H, Yasuda O, Ogawa H, Kim-Mitsuyama S . Nifedipine prevents vascular endothelial dysfunction in a mouse model of obesity and type 2 diabetes, by improving eNOS dysfunction and dephosphorylation. Biochem Bbiophys Res Commun 2010; 403: 258–263.

    Article  CAS  Google Scholar 

  12. 12

    Nomura S, Inami N, Kimura Y, Omoto S, Shouzu A, Nishikawa M, Iwasaka T . Effect of nifedipine on adiponectin in hypertensive patients with type 2 diabetes mellitus. J Hum Hypertens 2007; 21: 38–44.

    Article  CAS  PubMed  Google Scholar 

  13. 13

    Matsumori A, Nunokawa Y, Sasayama S . Nifedipine inhibits activation of transcription factor NF-κB. Life Sci 2000; 67: 2655–2661.

    Article  CAS  Google Scholar 

  14. 14

    Lupo E, Locher R, Weisser B, Vetter W . In vitro antioxidant activity of calcium antagonists against LDL oxidation compared with α-tocopherol. Biochem Biophys Res Commun 1994; 203: 1803–1808.

    Article  CAS  PubMed  Google Scholar 

  15. 15

    Hashimoto R, Umemoto S, Guo F, Umeji K, Itoh S, Kishi H, Kobayashi S, Matsuzaki M . Nifedipine activates PPARγ and exerts antioxidative action through Cu/ZnSOD independent of blood-pressure lowering in SHRSP. J Atheroscler Thromb 2010; 17: 785–795.

    Article  CAS  PubMed  Google Scholar 

  16. 16

    Subudhi BB, Sahoo SP . Synthesis and evaluation of antioxidant, anti-inflammatory and antiulcer activity of conjugates of amino acids with Nifedipine. Chem Pharm Bull 2011; 59: 1153–1156.

    Article  CAS  PubMed  Google Scholar 

  17. 17

    Rosenkranz AC, Lob H, Breitenbach T, Be JP . Endothelial antioxidant actions of dihydropyridines and angiotensin converting enzyme inhibitors. Eur J Pharmacol 2006; 529: 55–62.

    Article  CAS  PubMed  Google Scholar 

  18. 18

    Berkels R, Egink G, Marsen TA, Bartels H, Roesen R, Klaus W . Nifedipine increases endothelial nitric oxide bioavailability by antioxidative mechanisms. Hypertension 2001; 37: 240–245.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. 19

    Sakurada T, Ishizawa K, Imanishi M, Izawa-Ishizawa Y, Fujii S, Tominaga E, Tsuneishi T, Horinouchi Y, Kihira Y, Ikeda Y . Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects. Naunyn Schmiedeberg Arch Pharmacol 2013; 386: 29–39.

    Article  CAS  Google Scholar 

  20. 20

    Soe NN, Ishida T, Miho N, Ishida M, Sawano M, Abe K, Chayama K, Kihara Y, Yoshizumi M . Nifedipine interferes with migration of vascular smooth muscle cells via inhibition of Pyk2-Src axis. J Atheroscler Thromb 2009; 16: 230–238.

    Article  CAS  PubMed  Google Scholar 

  21. 21

    Motro M, Shemesh J . Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 2001; 37: 1410–1413.

    Article  CAS  PubMed  Google Scholar 

  22. 22

    Matsui T, Takeuchi M, Yamagishi S-i . Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity. Biochem Biophys Res Commun 2010; 396: 566–570.

    Article  CAS  PubMed  Google Scholar 

  23. 23

    Matsui T, Yamagishi S-i, Takeuchi M, Ueda S, Fukami K, Okuda S . Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation. Biochem Biophys Res Commun 2009; 385: 269–272.

    Article  CAS  PubMed  Google Scholar 

  24. 24

    Gao X, Iwai M, Inaba S, Tomono Y, Kanno H, Mogi M, Horiuchi M . Attenuation of monocyte chemoattractant protein-1 expression via inhibition of nuclear factor-κB activity in inflammatory vascular injury. Am J Hypertens 2007; 20: 1170–1175.

    CAS  PubMed  Google Scholar 

  25. 25

    Berkels R, Taubert D, Bartels H, Breitenbach T, Klaus W, Roesen R . Amlodipine increases endothelial nitric oxide by dual mechanisms. Pharmacology 2004; 70: 39–45.

    Article  CAS  PubMed  Google Scholar 

  26. 26

    Matsumori A, Nishio R, Nose Y . Calcium channel blockers differentially modulate cytokine production by peripheral blood mononuclear cells. Circ J 2010; 74: 567–571.

    Article  CAS  PubMed  Google Scholar 

  27. 27

    Kataoka C, Egashira K, Ishibashi M, Inoue S, Ni W, Hiasa K-i, Kitamoto S, Usui M, Takeshita A . Novel anti-inflammatory actions of amlodipine in a rat model of arteriosclerosis induced by long-term inhibition of nitric oxide synthesis. Am J Physiol Heart Circ Physiol 2004; 286: H768–H774.

    Article  CAS  PubMed  Google Scholar 

  28. 28

    Sueta D, Nakamura T, Dong Y-F, Kataoka K, Koibuchi N, Yamamoto E, Toyama K, Yasuda O, Ogawa H, Kim-Mitsuyama S . Amlodipine enhances amelioration of vascular insulin resistance, oxidative stress, and metabolic disorders by candesartan in metabolic syndrome rats. Am J Hypertens 2012; 25: 704–710.

    Article  CAS  PubMed  Google Scholar 

  29. 29

    Tulenko T, Sumner A, Chen M, Huang Y, Laury-Kleintop L, Ferdinand F . The smooth muscle cell membrane during atherogenesis: a potential target for amlodipine in atheroprotection. Am Heart J 2001; 141: S1–S11.

    Article  CAS  PubMed  Google Scholar 

  30. 30

    Mason RP . Mechanisms of atherosclerotic plaque stabilization for a lipophilic calcium antagonist amlodipine. Am Cardiol 2001; 88: 2–6.

    Article  Google Scholar 

  31. 31

    Shimamoto K, Ando K, Fujita T, Hasebe N, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ishimitsu T, Ito M . The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2014). Hypertens Res 2014; 37: 253–390.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. 32

    Taira N . Differences in cardiovascular profile among calcium antagonists. Am J Cardiol 1987; 59: B24–B29.

    Article  Google Scholar 

  33. 33

    Abernethy DR, Schwartz JB . Calcium-antagonist drugs. N Engl J Med 1999; 341: 1447–1457.

    Article  CAS  PubMed  Google Scholar 

  34. 34

    Antman E, Muller J, Goldberg S, MacAlpin R, Rubenfire M, Tabatznik B, Liang C-s, Heupler F, Achuff S, Reicher N . Nifedipine therapy for coronary-artery spasm: experience in 127 patients. N Engl J Med 1980; 302: 1269–1273.

    Article  CAS  PubMed  Google Scholar 

  35. 35

    Kimura E, Kishida H . Treatment of variant angina with drugs: a survey of 11 cardiology institutes in Japan. Circulation 1981; 63: 844–848.

    Article  CAS  PubMed  Google Scholar 

  36. 36

    Ginsburg R, Lamb IH, Schroeder JS, Hu M, Harrison DC . Randomized double-blind comparison of nifedipine and isosorbide dinitrate therapy in variant angina pectoris due to coronary artery spasm. Am Heart J 1982; 103: 44–48.

    Article  CAS  PubMed  Google Scholar 

  37. 37

    Mauritson DR, Johnson SM, Winniford MD, Cary JR, Willerson JT, Hillis LD . Verapamil for unstable angina at rest: A short-term randomized, double-blind study. Am Heart J 1983; 106: 652–658.

    Article  CAS  PubMed  Google Scholar 

  38. 38

    Pesola A, Lauro A, Gallo R, Madeo A, Cosentino G . Efficacy of diltiazem in variant angina. Results of a double-blind crossover study in CCU by Holter monitoring. The possible occurrence of a withdrawal syndrome. G Ital Cardiol 1987; 17: 329–339.

    CAS  PubMed  Google Scholar 

  39. 39

    Chahine RA, Feldman RL, Giles TD, Nicod P, Raizner AE, Weiss RJ, Vanov SK . Randomized placebo-controlled trial of amlodipine in vasospastic angina. J Am Coll Cardiol 1993; 21: 1365–1370.

    Article  CAS  PubMed  Google Scholar 

  40. 40

    Oikawa Y, Matsuno S, Yajima J, Nakamura M, Ono T, Ishiwata S, Fujimoto Y, Aizawa T . Effects of treatment with once-daily nifedipine CR and twice-daily benidipine on prevention of symptomatic attacks in patients with coronary spastic angina pectoris—Adalat Trial vs. Coniel in Tokyo against Coronary Spastic Angina (ATTACK CSA). J Cardiol 2010; 55: 238–247.

    Article  PubMed  Google Scholar 

  41. 41

    Higuma T, Oikawa K, Kato T, Mori Y, Kudo T, Yamamoto T, Hoshi Y, Kameda K, Suto N, Fujita N . Comparison of the effects of long-acting nifedipine CR and diltiazem R in patients with vasospastic angina: Aomori coronary spastic angina study. J Cardiol 2010; 56: 354–360.

    Article  PubMed  Google Scholar 

  42. 42

    Hata T, Soga J, Hidaka T, Idei N, Fujii Y, Fujimura N, Mikami S, Maruhashi T, Kihara Y, Chayama K . Calcium channel blocker and Rho-associated kinase activity in patients with hypertension. J Hypertens 2011; 29: 373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. 43

    Ito A, Fukumoto Y, Shimokawa H . Changing characteristics of patients with vasospastic angina in the era of new calcium channel blockers. J Cardiovasc Pharmacol 2004; 44: 480–485.

    Article  CAS  PubMed  Google Scholar 

  44. 44

    Nishigaki K, Inoue Y, Yamanouchi Y, Fukumoto Y, Yasuda S, Sueda S, Urata H, Shimokawa H, Minatoguchi S . Prognostic effects of calcium channel blockers in patients with vasospastic angina-a meta-analysis. Circ J 2010; 74: 1943–1950.

    Article  PubMed  Google Scholar 

  45. 45

    Lette J, Gagnon R-M, Lemire JG, Morissette M . Rebound of vasospastic angina after cessation of long-term treatment with nifedipine. Can Med Assoc J 1984; 130: 1169.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. 46

    Kozeny G, Ragona B, Bansal V, Hurley R, Dixon DW, Vertuno L, Hano J . Myocardial infarction with normal results of coronary angiography following diltiazem withdrawal. Am J Med 1986; 80: 1184–1186.

    Article  CAS  PubMed  Google Scholar 

  47. 47

    Kostis WJ, Suh WM, Palacios IF . Acute myocardial infarction caused by multivessel coronary spasm due to calcium channel blocker withdrawal. Catheter Cardiovasc Interv 2011; 78: 229–233.

    Article  PubMed  Google Scholar 

  48. 48

    tashiro H, Shimokawa H, Koyanagi S, Takeshita A . Clinical characteristics of patients with spontaneous remission of variant angina. Jpn Circ J 1993; 57: 117–122.

    Article  CAS  PubMed  Google Scholar 

  49. 49

    Waters DD, Bouchard A, ThÉroux P . Spontaneous remission is a frequent outcome of variant angina. J Am Coll Cardiol 1983; 2: 195–199.

    Article  CAS  PubMed  Google Scholar 

  50. 50

    Pristipino C, Beltrame JF, Finocchiaro ML, Hattori R, Fujita M, Mongiardo R, Cianflone D, Sanna T, Sasayama S, Maseri A . Major racial differences in coronary constrictor response between Japanese and Caucasians with recent myocardial infarction. Circulation 2000; 101: 1102–1108.

    Article  CAS  PubMed  Google Scholar 

  51. 51

    Group JJW. Guidelines for diagnosis and treatment of patients with vasospastic angina (Coronary Spastic Angina)(JCS 2013). Circ J 2014; 78: 2779.

    Article  Google Scholar 

  52. 52

    Mizuno Y, Harada E, Morita S, Kinoshita K, Hayashida M, Shono M, Morikawa Y, Murohara T, Nakayama M, Yoshimura M . East Asian variant of aldehyde dehydrogenase 2 (ALDH2* 2) is associated with coronary spastic angina: possible roles of reactive aldehydes and implications of alcohol flushing syndrome. Circulation 2015; 114: 013120.

    Google Scholar 

  53. 53

    Ishii M, Kaikita K, Sato K, Yamanaga K, Miyazaki T, Akasaka T, Tabata N, Arima Y, Sueta D, Sakamoto K . Impact of aspirin on the prognosis in patients with coronary spasm without significant atherosclerotic stenosis. Int J Cardiol 2016; 220: 328–332.

    Article  PubMed  Google Scholar 

  54. 54

    Ishii M, Kaikita K, Sato K, Yamanaga K, Miyazaki T, Akasaka T, Tabata N, Arima Y, Sueta D, Sakamoto K . Impact of statin therapy on clinical outcome in patients with coronary spasm. J Am Heart Assoc 2016; 5: e003426.

    Article  PubMed  PubMed Central  Google Scholar 

  55. 55

    Furberg CD, Psaty BM, Meyer JV . Nifedipine dose-related increase in mortality in patients with coronary heart disease. Circulation 1995; 92: 1326–1331.

    Article  CAS  PubMed  Google Scholar 

  56. 56

    Opie LH, Messerli FH . Nifedipine and mortality grave defects in the dossier. Circulation 1995; 92: 1068–1073.

    Article  CAS  PubMed  Google Scholar 

  57. 57

    Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, Rosendaal FR, Lemaitre RN, Smith NL, Wahl PW . The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995; 274: 620–625.

    Article  CAS  PubMed  Google Scholar 

  58. 58

    Ishikawa K, Nakai S, Takenaka T, Kanamasa K, Hama J, Ogawa I, Yamamoto T, Oyaizu M, Kimura A, Yamamoto K . Short-acting nifedipine and diltiazem do not reduce the incidence of cardiac events in patients with healed myocardial infarction. Circulation 1997; 95: 2368–2373.

    Article  CAS  PubMed  Google Scholar 

  59. 59

    Yusuf S . Calciumantagonists in coronary artery disease and hypertension time for reevaluation? Circulation 1995; 92: 1079–1082.

    Article  CAS  PubMed  Google Scholar 

  60. 60

    Eisenberg MJ, Brox A, Bestawros AN . Calcium channel blockers: an update. Am J Med 2004; 116: 35–43.

    Article  CAS  PubMed  Google Scholar 

  61. 61

    Poole-Wilson PA, Lubsen J, Kirwan B-A, van Dalen FJ, Wagener G, Danchin N, Just H, Fox KA, Pocock SJ, Clayton TC . Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet 2004; 364: 849–857.

    Article  CAS  PubMed  Google Scholar 

  62. 62

    Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol EJ . Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA 2004; 292: 2217–2225.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. 63

    Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M . A calcium antagonist vs. a non–calcium antagonist hypertension treatment strategy for patients with coronary artery disease: the International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290: 2805–2816.

    Article  CAS  PubMed  Google Scholar 

  64. 64

    Black HR, Elliott WJ, Grandits G, Grambsch P, Lucente T, White WB, Neaton JD, Grimm RH Jr, Hansson L, Lacourcière Y . Principal results of the controlled onset verapamil investigation of cardiovascular end points (CONVINCE) trial. JAMA 2003; 289: 2073–2082.

    Article  CAS  PubMed  Google Scholar 

  65. 65

    Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ . Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–2428.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  66. 66

    Wakabayashi K, Suzuki H, Honda Y, Wakatsuki D, Kawachi K, Ota K, Koba S, Shimizu N, Asano F, Sato T . Provoked coronary spasm predicts adverse outcome in patients with acute myocardial infarction: a novel predictor of prognosis after acute myocardial infarction. J Am Coll Cardiol 2008; 52: 518–522.

    Article  PubMed  Google Scholar 

  67. 67

    Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ . Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 2010; 304: 61–68.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. 68

    Bangalore S, Messerli FH, Cohen JD, Bacher PH, Sleight P, Mancia G, Kowey P, Zhou Q, Champion A, Pepine CJ . Verapamil-sustained release–based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: an INternational VErapamil SR-Trandolapril (INVEST) substudy. Am Heart J 2008; 156: 241–247.

    Article  CAS  PubMed  Google Scholar 

  69. 69

    Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es G-A, Steg PG, Morel M-a, Mauri L, Vranckx P . Clinical end points in coronary stent trials a case for standardized definitions. Circulation 2007; 115: 2344–2351.

    Article  PubMed  Google Scholar 

  70. 70

    Mauri L, Hsieh W-h, Massaro JM, Ho KK, D'Agostino R, Cutlip DE . Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356: 1020–1029.

    Article  CAS  PubMed  Google Scholar 

  71. 71

    Capone G, Wolf NM, Meyer B, Meister SG . Frequency of intracoronary filling defects by angiography in angina pectoris at rest. Am J Cardiol 1985; 56: 403–406.

    Article  CAS  PubMed  Google Scholar 

  72. 72

    Al Suwaidi J, Holmes DR, Salam AM, Lennon R, Berger PB . Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Am Heart J 2004; 147: 815–822.

    Article  PubMed  Google Scholar 

  73. 73

    Kimura T, Morimoto T, Nakagawa Y, Tamura T, Kadota K, Yasumoto H, Nishikawa H, Hiasa Y, Muramatsu T, Meguro T . Antiplatelet therapy and stent thrombosis after sirolimus-eluting stent implantation. Circulation 2009; 119: 987–995.

    Article  CAS  PubMed  Google Scholar 

  74. 74

    Dangas GD, Caixeta A, Mehran R, Parise H, Lansky AJ, Cristea E, Brodie BR, Witzenbichler B, Guagliumi G, Peruga JZ . Frequency and predictors of stent thrombosis after percutaneous coronary intervention in acute myocardial infarction. Circulation 2011; 123: 1745–1756.

    Article  PubMed  Google Scholar 

  75. 75

    King SB, Smith SC, Hirshfeld JW, Jacobs AK, Morrison DA, Williams DO, Feldman TE, Kern MJ, O’Neill WW, Schaff HV . 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention a Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention Writing on Behalf of the 2005 Writing Committee. Circulation 2008; 117: 261–295.

    Article  PubMed  Google Scholar 

  76. 76

    Kushner FG, Hand M, Smith SC, King SB, Anderson JL, Antman EM, Bailey SR, Bates ER, Blankenship JC, Casey DE . 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54: 2205–2241.

    Article  PubMed  Google Scholar 

  77. 77

    Chitose T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, Shimomura H, Tsunoda R, Maruyama H, Hirose T . Clinical outcomes following coronary stenting in Japanese patients treated with and without proton pump inhibitor. Circ J 2012; 76: 71–78.

    Article  CAS  PubMed  Google Scholar 

  78. 78

    Akasaka T, Hokimoto S, Oshima S, Nakao K, Fujimoto K, Miyao Y, Shimomura H, Tsunoda R, Hirose T, Kajiwara I . Clinical outcomes of percutaneous coronary intervention (PCI) at hospital with or without onsite cardiac surgery backup. Int J Cardiol 2014; 176: 1385.

    Article  PubMed  Google Scholar 

  79. 79

    Ishii M, Hokimoto S, Akasaka T, Fujimoto K, Miyao Y, Kaikita K, Oshima S, Nakao K, Shimomura H, Tsunoda R . Differential effects of strong and regular statins on the clinical outcome of patients with chronic kidney disease following coronary stent implantation. Circ J 2015; 79: 1115–1124.

    Article  PubMed  Google Scholar 

  80. 80

    Akasaka T, Hokimoto S, Sueta D, Tabata N, Oshima S, Nakao K, Fujimoto K, Miyao Y, Shimomura H, Tsunoda R . Clinical outcomes of percutaneous coronary intervention for acute coronary syndrome between hospitals with and without onsite cardiac surgery backup. J Cardiol 2016; 69: 103–109.

    Article  PubMed  Google Scholar 

  81. 81

    Nagano M, Hokimoto S, Nakao K, Kaikita K, Akasaka T, Ogawa H . Relation between stent thrombosis and calcium channel blocker after drug-eluting stent implantation: Kumamoto Intervention Conference Study (KICS) registry. J Cardiol 2015; 66: 333–340.

    Article  PubMed  Google Scholar 

  82. 82

    Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O’Rourke M, Investigators C. Differential impact of blood pressure–lowering drugs on central aortic pressure and clinical outcomes principal results of the Conduit Artery Function Evaluation (CAFE) Study. Circulation 2006; 113: 1213–1225.

    Article  CAS  PubMed  Google Scholar 

  83. 83

    Tokitsu T, Yamamoto E, Hirata Y, Fujisue K, Sugamura K, Maeda H, Tsujita K, Kaikita K, Hokimoto S, Sugiyama S . Relationship between inter-arm blood pressure differences and future cardiovascular events in coronary artery disease. J Hypertens 2015; 33: 1780–1790.

    Article  CAS  PubMed  Google Scholar 

  84. 84

    Thamcharoen N, Susantitaphong P, Wongrakpanich S, Chongsathidkiat P, Tantrachoti P, Pitukweerakul S, Avihingsanon Y, Praditpornsilpa K, Jaber BL, Eiam-Ong S . Effect of N-and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis. Hypertens Res 2015; 38: 847–855.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  85. 85

    Nagasawa K, Takahashi K, Matsuura N, Takatsu M, Hattori T, Watanabe S, Harada E, Niinuma K, Murohara T, Nagata K . Comparative effects of valsartan in combination with cilnidipine or amlodipine on cardiac remodeling and diastolic dysfunction in Dahl salt-sensitive rats. Hypertens Res 2015; 38: 39–47.

    Article  CAS  PubMed  Google Scholar 

  86. 86

    Hasebe N, Kikuchi K, Group NCS. Controlled-release nifedipine and candesartan low-dose combination therapy in patients with essential hypertension: the NICE Combi (Nifedipine and Candesartan Combination) Study. J Hypertens 2005; 23: 445–453.

    Article  CAS  PubMed  Google Scholar 

  87. 87

    Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlöf B, Kelly RY, Hua TA . Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol 2010; 56: 77–85.

    Article  CAS  PubMed  Google Scholar 

  88. 88

    Bakris GL, Sarafidis PA, Weir MR, Dahlöf B, Pitt B, Jamerson K, Velazquez EJ, Staikos-Byrne L, Kelly RY, Shi V . Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173–1181.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. 89

    Ogawa H, Kim-Mitsuyama S, Matsui K, Jinnouchi T, Jinnouchi H, Arakawa K . Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients. Am J Med 2012; 125: 981–990.

    Article  CAS  PubMed  Google Scholar 

  90. 90

    Ishimitsu T, Kameda T, Akashiba A, Takahashi T, Ohta S, Yoshii M, Minami J, Ono H, Numabe A, Matsuoka H . Efonidipine reduces proteinuria and plasma aldosterone in patients with chronic glomerulonephritis. Hypertens Res 2007; 30: 621–626.

    Article  CAS  PubMed  Google Scholar 

  91. 91

    Isaka T, Ikeda K, Takada Y, Inada Y, Tojo K, Tajima N . Azelnidipine inhibits aldosterone synthesis and secretion in human adrenocortical cell line NCI-H295R. Eur J Pharmacol 2009; 605: 49–52.

    Article  CAS  PubMed  Google Scholar 

  92. 92

    Dietz JD, Du S, Bolten CW, Payne MA, Xia C, Blinn JR, Funder JW, Hu X . A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008; 51: 742–748.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank all the paramedical staff and clinical secretaries for their kind support during the course of this work.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Seiji Hokimoto.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sueta, D., Tabata, N. & Hokimoto, S. Clinical roles of calcium channel blockers in ischemic heart diseases. Hypertens Res 40, 423–428 (2017). https://doi.org/10.1038/hr.2016.183

Download citation

Further reading

Search

Quick links